Role of intermittent hypoxia in the treatment of bronchial asthma and chronic obstructive pulmonary disease

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 3, 2010, Pages 206-213

  Vogtel, Myriam ^a   Michels, Alexandra ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Hypoxia; Intermittent hypoxic training

Indexed keywords

CARBON MONOXIDE; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1;

ASSISTED VENTILATION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; HUMAN; HYPERCAPNIA; HYPOXIA; IMMUNE RESPONSE; INTERMITTENT HYPOXIC TRAINING; IRON METABOLISM; LUNG DIFFUSION CAPACITY; NONHUMAN; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; REVIEW;

ANOXIA; ASTHMA; COMBINED MODALITY THERAPY; EXERCISE THERAPY; HUMANS; OXYGEN CONSUMPTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 77951878397     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833903a6     Document Type: Review

References (56)

1. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:502-506.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478.
3. WHO. Chronic obstructive pulmonary disease (COPD). 2009. http://www.who.int/respiratory/copd/en/. [Accessed 21 December 2009]
4. Hizawa N. Genetic backgrounds of asthma and COPD. Allergol Int 2009;58:315-322.
5. Ichinose M. Differences of inflammatory mechanisms in asthma and COPD. Allergol Int 2009;58:307-313.
6. Mishima M. Physiological differences and similarities in asthma and COPD-• based on respiratory function testing. Allergol Int 2009;58:333-340. This study describes the distinct inflammatory pattern in bronchial asthma and COPD.
7. Gordon E, Lazarus SC. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm. J Allergy Clin Immunol 2009;124:873-880; quiz 881-882.
8. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc 2009;6:638-647.
9. Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease GOLD Executive Summary. Am J Respir Crit Care Med 2007;176:532-555.
10. COPD: more than just tobacco smoke. Lancet 2009 Aug. 29; 374 (9691):663.
11. GINA. GIfA. Global strategy for asthma managment and prevention. 2008. http://www.ginasthma.com/Guidelineitem.aspl1=2&l2=1&intId=1 561. [Accessed 21 March 2010]
12. Zhong H, Belardinelli L, Maa T, Zeng D. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2005;32:2-8.
13. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-5454.
14. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008;15:621-627.
15. Steinke JW, Woodard CR, Borish L. Role of hypoxia in inflammatory upper airway disease. Curr Opin Allergy Clin Immunol 2008;8:16-20.
16. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17:71-77.
17. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
18. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
19. Fukuda R, Zhang H, Kim JW, et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007;129:111-122.
20. Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell 1997;89:9-12.
21. Galson DL, Tsuchiya T, Tendler DS, et al. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxiaspecific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol Cell Biol 1995;15:2135-2144.
22. Lemus-Varela ML, Flores-Soto ME, Cervantes-Munguia R, et al. Expression of • HIF-1alpha, VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia. Clin Biochem 2010;43:234-239. HIF-1 a mRNA increases in newborn infants with Persistent pulmonary hypertension of the newborn (PPHN) or cyanotic congenital heart disease (CCHD), as does the expression of its target genes VEGF and EPO.
23. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-578.
24. Gassmann M, Tissot van Patot M, Soliz J. The neuronal control of hypoxic •• ventilation: erythropoietin and sexual dimorphism. Ann N Y Acad Sci 2009;1177:151-161. It was shown that enhanced EPO levels in the brainstem increased the HVR, and that intracerebroventricular injection of an EPO antagonist abolished the ventilatory acclimatization on hypoxia. The impact of EPO on ventilation occurs in a sexdependent manner.
25. Gassmann M, Heinicke K, Soliz J, Ogunshola OO. Nonerythroid functions of erythropoietin. Adv Exp Med Biol 2003;543:323-330.
26. Murakami T, Ilieva H, Shiote M, et al. Hypoxic induction of vascular endothelial growth factor is selectively impaired in mice carrying the mutant SOD1 gene. Brain Res 2003;989:231-237.
27. Yamaji-Kegan K, Su Q, Angelini DJ, Johns RA. IL-4 is proangiogenic in the lung • under hypoxic conditions. J Immunol 2009;182:5469-5476. IL-4 has proangiogenic properties in the lung under hypoxic conditions via the VEGF pathway, and this is independent of the signal transducer and activator of transcription 6, interleukin-4 induced (STAT6) pathway.
28. Asai K, Kanazawa H, Kamoi H, et al. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy 2003;33:595-599.
29. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001;107:295-301.
30. Chetta A, Zanini A, Foresi A, et al. Vascular endothelial growth factor upregulation and bronchial wall remodelling in asthma. Clin Exp Allergy 2005;35:1437-1442.
31. Papaioannou AI, Kostikas K, Kollia P, Gourgoulianis KI. Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res 2006;7:128.
32. Mazza E, Thakkar-Varia S, Tozzi CA, Neubauer JA. Expression of heme oxygenase in the oxygen-sensing regions of the rostral ventrolateral medulla. J Appl Physiol 2001;91:379-385.
33. Zhang H, Chamba Y, Zhao CJ, et al. Function of inducible nitric oxide synthase on adaptability to hypoxia in Tibetan chicken. Yi Chuan 2009;31:400-406.
34. Ward ME, Toporsian M, Scott JA, et al. Hypoxia induces a functionally significant and translationally efficient neuronal NO synthase mRNA variant. J Clin Invest 2005;115:3128-3139.
35. El Hasnaoui-Saadani R, Alayza RC, Launay T, et al. Brain stem NO modulates ventilatory acclimatization to hypoxia in mice. J Appl Physiol 2007;103:1506-1512.
36. Powell FL, Fu Z. HIF-1 and ventilatory acclimatization to chronic hypoxia. •• Respir Physiol Neurobiol 2008;164(1-2): 282-287. HIF-1 a produces a suite of coordinated responses to chronic hypoxia. These effects differ between chronic intermittent and sustained hypoxia. Experimental manipulations of HIF-1 α in specific pathways of ventilatory acclimatization may help to detect the integrated response to various patterns of hypoxia.
37. Poyton RO, Castello PR, Ball KA, et al. Mitochondria and hypoxic signaling: a •• new view. Ann N Y Acad Sci 2009;1177:48-56. The activity called Cco/nitric oxide is incorporated into a new model for hypoxic signalling. It was found that some of the nitric oxide produced by Cco/nitric oxide is released from cells, raising the possibility that mitochondrially generated nitric oxide also functions in extracellular hypoxic signalling pathways.
38. Wenger RH. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 2000;203(Pt 8):1253-1263.
39. Millhorn DE, Raymond R, Conforti L, et al. Regulation of gene expression for tyrosine hydroxylase in oxygen sensitive cells by hypoxia. Kidney Int 1997;51:527-535.
40. Pascual O, Denavit-Saubie M, Dumas S, et al. Selective cardiorespiratory and catecholaminergic areas express the hypoxia-inducible factor-1alpha (HIF-1alpha) under in vivo hypoxia in rat brainstem. Eur J Neurosci 2001;14:1981-1991.
41. Lam SY, Tipoe GL, Liong EC, Fung ML. Differential expressions and roles of hypoxia-inducible factor-1alpha,-2alpha and-3alpha in the rat carotid body during chronic and intermittent hypoxia. Histol Histopathol 2008;23:271-280.
42. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 2008;7:28-32.
43. Neubauer JA. Invited review: physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol 2001;90:1593-1599.
44. Serebrovskaya TV, Swanson RJ, Kolesnikova EE. Intermittent hypoxia: mechanisms of action and some applications to bronchial asthma treatment. J Physiol Pharmacol 2003;54(Suppl 1):35-41.
45. Haider T, Casucci G, Linser T, et al. Interval hypoxic training improves •• autonomic cardiovascular and respiratory control in patients with mild chronic obstructive pulmonary disease. J Hypertens 2009;27:1648-1654. After 3 weeks of training with passive intermittent hypoxia, the patients showed increased baroreflex sensitivity up to normal levels and selectively increased HCVR.
46. Fu Q, Townsend NE, Shiller SM, et al. Intermittent hypobaric hypoxia exposure does not cause sustained alterations in autonomic control of blood pressure in young athletes. Am J Physiol Regul Integr Comp Physiol 2007;292:R1977-R1984.
47. Ainslie PN, Kolb JC, Ide K, Poulin MJ. Effects of five nights of normobaric hypoxia on the ventilatory responses to acute hypoxia and hypercapnia. Respir Physiol Neurobiol 2003;138(2-3): 193-204.
48. Townsend NE, Gore CJ, Hahn AG, et al. Hypoxic ventilatory response is correlated with increased submaximal exercise ventilation after live high, train low. Eur J Appl Physiol 2005;94(1-2): 207-215.
49. Katayama K, Ishida K, Iwasaki K, Miyamura M. Effect of two durations of short-•• term intermittent hypoxia on ventilatory chemosensitivity in humans. Eur J Appl Physiol 2009;105:815-821. Concerning the influence of duration of intermittent hypoxia per day on ventilatory chemosensitivity, it was found that 1 h of daily exposure is as equally effective as 3 h of daily exposure to severe hypoxia.
50. Burtscher M, Haider T, Domej W, et al. Intermittent hypoxia increases exercise •• tolerance in patients at risk for or with mild COPD. Respir Physiol Neurobiol 2009;165:97-103. Three weeks of intermittent hypoxia increases total haemoglobin mass, total exercise time, and the exercise time to the anaerobic threshold.
51. Lundby C, Nielsen TK, Dela F, Damsgaard R. The influence of intermittent altitude exposure to 4100 m on exercise capacity and blood variables. Scand J Med Sci Sports 2005;15:182-187.
52. Julian CG, Gore CJ, Wilber RL, et al. Intermittent normobaric hypoxia does not alter performance or erythropoietic markers in highly trained distance runners. J Appl Physiol 2004;96:1800-1807.
53. Gore CJ, Rodriguez FA, Truijens MJ, et al. Increased serum erythropoietin but not red cell production after 4 wk of intermittent hypobaric hypoxia (4000-5500 m). J Appl Physiol 2006;101:1386-1393.
54. Burtscher M, Gatterer H, Szubski C, et al. Effects of interval hypoxia on •• exercise tolerance: special focus on patients with CAD or COPD. Sleep Breath. 2009 Aug. 18. [Epub ahead of print] The effects of 2-4 weeks of interval hypoxia on exercise tolerance are different. Whereas aerobic exercise performance improved or remained unchanged, anaerobic performance tended even to worsen.
55. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167:544-549.
56. Bowen JB, Votto JJ, Thrall RS, et al. Functional status and survival following pulmonary rehabilitation. Chest 2000;118:697-703.